ASP Isotopes Inc. 8-K/A

What Happened
ASP Isotopes Inc. (ASPI) filed an amendment to its Closing Form 8-K on March 24, 2026 (Item 9.01) to include the required financial statements and unaudited pro forma combined condensed financial statements as exhibits. The filing says these pro forma statements are provided for informational purposes only, were prepared as required by Form 8-K, and do not represent the actual results the companies would have achieved if ASP Isotopes and Renergen had been combined during the periods shown.

Key Details

• Filing type: Form 8-K/A, Item 9.01 (Financial Statements and Exhibits), filed March 24, 2026.
• Content added: unaudited pro forma combined condensed financial statements incorporated by reference as exhibits.
• Purpose statement: pro forma statements are informational only, not representations of actual historical results and not intended to project future performance of the combined company.
• All other information in the original Closing Form 8-K remains unchanged.

Why It Matters
The amendment supplies pro forma financial information tied to the Renergen transaction so investors can see a combined view on a preliminary basis. However, these are unaudited and explicitly not a substitute for audited results or an earnings forecast—investors should not treat them as actual historical earnings, revenue, or a projection of future performance. Retail investors reviewing the deal should read the exhibits for details and note that this filing updates only the exhibits portion of the prior Closing Form 8-K.